dings unre- lated to the indication for ordering the sequencing but of medical value for patient care. The American College of Medical Genetics and Genomics (ACMG) recently published a policy statement on clinical sequencing that emphasized the importance of alerting the patient to the possibility of su

transforming the way we think about disease and sit 1-on-1 with Joel T. Dudley, PhD, Director of Bioinformatics, and Elissa Levin, MS. CGC, Head of Genomics and Integrative Health Innovations, to help you and a guest demystify the brave new world of personal genomics. During this extraordinarily rare ed

transforming the way we think about disease and sit 1-on-1 with Joel T. Dudley, PhD, Director of Bioinformatics, and Elissa Levin, MS. CGC, Head of Genomics and Integrative Health Innovations, to help you and a guest demystify the brave new world of personal genomics. During this extraordinarily rare ed

and Fellows of Harvard College ("Harvard"), a Massachusetts educational and charitable corporation, creates a current-use fund to be designated the Genomics and Synthetic Biology Research Fund ("the Fund") at Harvard Medical School. Use of Fund The Fund will be under the direction of George M. Church,

n published on the cover in Nature in Oct 2005. ■ Editorial board of more than 20 journals including Science, PNAS, J.Mol. Biol., EMBO J.. RNA and Genomics. Business Biography ■ Co-Founder and the Co-Chairman of the Board of Directors of Repligen Corporation (NASDAQ: RGEN), a biopharmaceutical compan

expected to grow at a CAGR of 72% from 5511m in 2013 to 57.6bn in 20185. Molecular profiling will also enable better risk prediction and prognosis. Genomics will have the highest impact on cancer prediction and prognosis. Cancer is a disease that is driven entirely by complex and highly individual DNA c